These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 25432430)

  • 1. Critical period for dopaminergic neuroprotection by hormonal replacement in menopausal rats.
    Rodriguez-Perez AI; Borrajo A; Valenzuela R; Lanciego JL; Labandeira-Garcia JL
    Neurobiol Aging; 2015 Feb; 36(2):1194-208. PubMed ID: 25432430
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Menopause and Parkinson's disease. Interaction between estrogens and brain renin-angiotensin system in dopaminergic degeneration.
    Labandeira-Garcia JL; Rodriguez-Perez AI; Valenzuela R; Costa-Besada MA; Guerra MJ
    Front Neuroendocrinol; 2016 Oct; 43():44-59. PubMed ID: 27693730
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dopaminergic neuroprotection of hormonal replacement therapy in young and aged menopausal rats: role of the brain angiotensin system.
    Rodriguez-Perez AI; Valenzuela R; Villar-Cheda B; Guerra MJ; Labandeira-Garcia JL
    Brain; 2012 Jan; 135(Pt 1):124-38. PubMed ID: 22189567
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Estrogen and angiotensin interaction in the substantia nigra. Relevance to postmenopausal Parkinson's disease.
    Rodriguez-Perez AI; Valenzuela R; Villar-Cheda B; Guerra MJ; Lanciego JL; Labandeira-Garcia JL
    Exp Neurol; 2010 Aug; 224(2):517-26. PubMed ID: 20580712
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Estrogen protects the dopaminergic neurons in substantia nigra against damage induced by 6-hydroxydopamine].
    Meng JL; Ma YY; Luo HY; Kong SZ; He YW; Dong BC; Wu SH; He M
    Sheng Li Xue Bao; 2008 Jun; 60(3):369-74. PubMed ID: 18560728
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of Rho kinase mediates the neuroprotective effects of estrogen in the MPTP model of Parkinson's disease.
    Rodriguez-Perez AI; Dominguez-Meijide A; Lanciego JL; Guerra MJ; Labandeira-Garcia JL
    Neurobiol Dis; 2013 Oct; 58():209-19. PubMed ID: 23774254
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aging-related changes in the nigral angiotensin system enhances proinflammatory and pro-oxidative markers and 6-OHDA-induced dopaminergic degeneration.
    Villar-Cheda B; Valenzuela R; Rodriguez-Perez AI; Guerra MJ; Labandeira-Garcia JL
    Neurobiol Aging; 2012 Jan; 33(1):204.e1-11. PubMed ID: 20888078
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rosiglitazone, a PPAR-γ agonist, protects against striatal dopaminergic neurodegeneration induced by 6-OHDA lesions in the substantia nigra of rats.
    Lee EY; Lee JE; Park JH; Shin IC; Koh HC
    Toxicol Lett; 2012 Sep; 213(3):332-44. PubMed ID: 22842585
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Involvement of microglial RhoA/Rho-kinase pathway activation in the dopaminergic neuron death. Role of angiotensin via angiotensin type 1 receptors.
    Villar-Cheda B; Dominguez-Meijide A; Joglar B; Rodriguez-Perez AI; Guerra MJ; Labandeira-Garcia JL
    Neurobiol Dis; 2012 Aug; 47(2):268-79. PubMed ID: 22542954
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rho Kinase and Dopaminergic Degeneration: A Promising Therapeutic Target for Parkinson's Disease.
    Labandeira-Garcia JL; Rodríguez-Perez AI; Villar-Cheda B; Borrajo A; Dominguez-Meijide A; Guerra MJ
    Neuroscientist; 2015 Dec; 21(6):616-29. PubMed ID: 25323761
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Estrogen, neuroinflammation and neuroprotection in Parkinson's disease: glia dictates resistance versus vulnerability to neurodegeneration.
    Morale MC; Serra PA; L'episcopo F; Tirolo C; Caniglia S; Testa N; Gennuso F; Giaquinta G; Rocchitta G; Desole MS; Miele E; Marchetti B
    Neuroscience; 2006; 138(3):869-78. PubMed ID: 16337092
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Brain angiotensin regulates iron homeostasis in dopaminergic neurons and microglial cells.
    Garrido-Gil P; Rodriguez-Pallares J; Dominguez-Meijide A; Guerra MJ; Labandeira-Garcia JL
    Exp Neurol; 2013 Dec; 250():384-96. PubMed ID: 24184051
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The possible role of estrogen and selective estrogen receptor modulators in a rat model of Parkinson's disease.
    Baraka AM; Korish AA; Soliman GA; Kamal H
    Life Sci; 2011 May; 88(19-20):879-85. PubMed ID: 21420980
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Crosstalk between insulin-like growth factor-1 and angiotensin-II in dopaminergic neurons and glial cells: role in neuroinflammation and aging.
    Rodriguez-Perez AI; Borrajo A; Diaz-Ruiz C; Garrido-Gil P; Labandeira-Garcia JL
    Oncotarget; 2016 May; 7(21):30049-67. PubMed ID: 27167199
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Chinese herbal formula Liuwei dihuang protects dopaminergic neurons against Parkinson's toxin through enhancing antioxidative defense and preventing apoptotic death.
    Tseng YT; Chang FR; Lo YC
    Phytomedicine; 2014 Apr; 21(5):724-33. PubMed ID: 24411708
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cannabinoids provide neuroprotection against 6-hydroxydopamine toxicity in vivo and in vitro: relevance to Parkinson's disease.
    Lastres-Becker I; Molina-Holgado F; Ramos JA; Mechoulam R; Fernández-Ruiz J
    Neurobiol Dis; 2005; 19(1-2):96-107. PubMed ID: 15837565
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dextromethorphan protects dopaminergic neurons against inflammation-mediated degeneration through inhibition of microglial activation.
    Liu Y; Qin L; Li G; Zhang W; An L; Liu B; Hong JS
    J Pharmacol Exp Ther; 2003 Apr; 305(1):212-8. PubMed ID: 12649371
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of the brain renin-angiotensin system in Parkinson´s disease.
    Labandeira-Garcia JL; Labandeira CM; Guerra MJ; Rodriguez-Perez AI
    Transl Neurodegener; 2024 Apr; 13(1):22. PubMed ID: 38622720
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of chronic treatment with angiotensin type 1 receptor antagonists on striatal dopamine levels in normal rats and in a rat model of Parkinson's disease treated with L-DOPA.
    Dominguez-Meijide A; Villar-Cheda B; Garrido-Gil P; Sierrra-Paredes G; Guerra MJ; Labandeira-Garcia JL
    Neuropharmacology; 2014 Jan; 76 Pt A():156-68. PubMed ID: 23973568
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Full and partial peroxisome proliferation-activated receptor-γ agonists, but not δ agonist, rescue of dopaminergic neurons in the 6-OHDA parkinsonian model is associated with inhibition of microglial activation and MMP expression.
    Sadeghian M; Marinova-Mutafchieva L; Broom L; Davis JB; Virley D; Medhurst AD; Dexter DT
    J Neuroimmunol; 2012 May; 246(1-2):69-77. PubMed ID: 22498097
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.